Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325791 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,177
- Enrollment target
- 20
- Study locations
NCT02325791 is a Phase 3 study of Respiratory Syncytial Virus Infections that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,177 participants, above the 1,035-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02325791, a Phase 3 study of Respiratory Syncytial Virus Infections, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,177 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.
Conditions Studied
Interventions
- DRUG Suptavumab 30 mg/kg
- DRUG Placebo Matched to Suptavumab
- DRUG Suptavumab 30 mg/kg- 1 Dose
- DRUG Suptavumab 30 mg/kg - 2 Doses
Study Locations (20)
California
- Regeneron Study Site - Anaheim
- Regeneron Study Site - Bell Gardens
- Regeneron Study Site - Dinuba
- Regeneron Study Site - Downey
- Regeneron Study Site - Huntington Beach
- Regeneron Study Site - La Puente
- Regeneron Study Site - Los Angeles
- Regeneron Study Site - Madera
- Regeneron Study Site - Palmdale
- Regeneron Study Site - Ventura
- Regeneron Study Site - West Covina
Florida
- Regeneron Study Site - Boynton Beach
- Regeneron Study Site - Gainesville
- Regeneron Study Site - Jacksonville
Alabama
- Regeneron Investigational Site - Birmingham
- Regeneron Study Site - Mobile
Colorado
- Regeneron Study Site - Aurora
- Regeneron Study Site - Thornton
Arkansas
- Regeneron Study Site - Little Rock
Connecticut
- Regeneron Study Site - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,177 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02325791
The ClinicalTrials.gov registry entry for NCT02325791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,177 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,035-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (14% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 4 interventions - of which Suptavumab 30 mg/kg is the first listed.
NCT02325791 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02325791 about?
NCT02325791 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants". The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In ...
What is the current status of trial NCT02325791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,177 participants. The study started on 2015-07-21. Estimated completion is 2017-09-26.
What conditions does trial NCT02325791 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT02325791?
The interventions under investigation include: Suptavumab 30 mg/kg (DRUG), Placebo Matched to Suptavumab (DRUG), Suptavumab 30 mg/kg- 1 Dose (DRUG), Suptavumab 30 mg/kg - 2 Doses (DRUG).
Who is sponsoring clinical trial NCT02325791?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02325791 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.